Data for Rivaroxaban presented at the ACC Scientific Sessions 2012

March 24 - 27, 2012
Chicago, IL, USA

Findings from the Phase III EINSTEIN-PE study were presented in the Late-Breaking Clinical Trials Session on March 26th, 2012, 08:00 – 09:30 a.m. CDT, at the American College of Cardiology’s 61st Annual Scientific Sessions (ACC) in Chicago, USA, by lead investigator Harry R. Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.

On this occasion we hosted a conference call for investors and analysts on March 26, 2012 at approx. 5:00 p.m. CEST (3:00 p.m. GMT).

Monday, March 26: Investor Conference Call on Rivaroxaban

Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Last updated: December 04, 2013 Copyright © Bayer AG